第4周应答预测基因3型HCV感染肝硬化患者全口服DAA治疗的SVR12
该研究基于西班牙33家医院的前瞻性多队列研究,纳入123例完成全口服DAA治疗的HCV基因3型感染患者,评估治疗第4周HCV-RNA应答对SVR12的预测能力。结果显示第4周HCV-RNA水平与SVR12显著相关(p=0.001),在肝硬化患者中同样显著(p=0.004),提示第4周应答可用于指导治疗策略。
要点
- 第4周HCV-RNA未检出者SVR12达98%,低于定量下限者为85.7%,≥定量下限者为75%。
- 肝硬化患者中对应SVR12分别为96.3%、77.8%和70%,线性关联p=0.004。
- 9例复发患者基线均存在肝硬化,第4周应答有助于识别高危患者。
核心结论
- 在HCV基因3型感染且伴肝硬化的患者中,治疗第4周应答可提示全口服DAA方案获得SVR12的概率。
研究设计与样本
- 前瞻性多队列研究,纳入西班牙33家医院123例完成当前推荐全口服DAA治疗且达到SVR12评估时间点的HCV基因3型感染患者。
主要发现
- 123例中114例(92.7%)获得SVR12,9例(7.3%)复发且基线均有肝硬化。
- 第4周HCV-RNA目标未检出、低于定量下限和≥定量下限者SVR12分别为81/83(98%;95%CI 91.5%-99.7%)、24/28(85.7%;95%CI 67.3%-96%)和9/12(75%;95%CI 42.8%-94.5%),p(线性关联)0.001。
- 肝硬化患者对应SVR12分别为52/54(96.3%;95%CI 87.3%-95.5%)、14/18(77.8%;95%CI 52.4%-93.6%)和7/10(70%;95%CI 34.8%-93.3%),p=0.004。
关键数值与推荐
- 第4周HCV-RNA应答分类:目标未检出(TND)、低于定量下限(LLOQTD)和≥定量下限(≥LLOQ)。
- 86例(70%)接受索磷布韦/达拉他韦±利巴韦林,27例(22%)接受索磷布韦/雷迪帕韦/利巴韦林,10例(8.1%)接受索磷布韦/利巴韦林。
临床怎么用
- 对HCV基因3型合并肝硬化患者,可依据治疗第4周HCV-RNA应答评估SVR12概率并调整治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to determine the predictive capacity of response at treatment week (TW) 4 for the achievement of sustained virological response 12 weeks after the scheduled end of therapy date (SVR12) to treatment against hepatitis C virus (HCV) genotype 3 (GT3) infection with all-oral direct-acting antiviral (DAA) -based regimens. PATIENTS AND METHODS: From a prospective multicohort study, HCV GT3-infected patients who completed a course of currently recommended DAA-based therapy at 33 Spanish hospitals and who had reached the SVR12 evaluation time-point were selected. TW4 HCV-RNA levels were categorized as target-not-detected (TND), below the lower limit of quantification (LLOQTD) and ≥LLOQ. RESULTS: A total of 123 patients were included, 86 (70%) received sofosbuvir/ daclatasvir±ribavirin, 27 (22%) received sofosbuvir/ ledipasvir/ ribavirin and 10 (8.1%) received sofosbuvir/ ribavirin, respectively. In all, 114 (92.7%) of the 123 patients presented SVR12 in an on-treatment approach, but nine (7.3%) patients relapsed, all of them had presented cirrhosis at baseline. In those who achieved TND, LLOQTD and ≥LLOQ, SVR12 was observed in 81/83 (98%; 95% CI 91.5%-99.7%), 24/28 (85.7%; 95% CI 67.3%-96%) and 9/12 (75%; 95% CI 42.8%-94.5%), respectively; p(linear association) 0.001. Corresponding numbers for subjects with cirrhosis were: 52/54 (96.3%; 95% CI 87.3%-95.5%), 14/18 (77.8%; 95% CI 52.4%-93.6%) and 7/10 (70%; 95% CI 34.8%-93.3%); p 0.004. CONCLUSIONS: TW4-response indicates the probability of achieving SVR12 to currently used DAA-based therapy in HCV genotype 3-infected individuals with cirrhosis. This finding may be useful to tailor treatment strategy in this setting.
引用
- Pineda JA, Morano-Amado LE, Granados R, et al. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. Clin Microbiol Infect. 2017. PMID: 28137633. doi:10.1016/j.cmi.2016.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。